Understanding how certain nanoparticles can help reduce unwanted immune responses
Lipid mediated oral tolerance
['FUNDING_R01'] · STATE UNIVERSITY OF NEW YORK AT BUFFALO · NIH-11088822
This study is looking at how tiny particles made from a natural substance can help deliver proteins through the mouth to help people with allergies and autoimmune diseases by reducing unwanted immune reactions, aiming to create a new treatment that could make managing these conditions easier and more effective.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | STATE UNIVERSITY OF NEW YORK AT BUFFALO (nih funded) |
| Locations | 1 site (AMHERST, UNITED STATES) |
| Trial ID | NIH-11088822 on ClinicalTrials.gov |
What this research studies
This research investigates how nanoparticles made from lyso-phosphatidylserine can be used to deliver proteins orally, potentially reducing unwanted immune responses associated with autoimmune conditions and allergies. By pre-administering these nanoparticles loaded with specific antigens, the study aims to uncover the cellular and molecular mechanisms that lead to oral tolerance. The goal is to develop a new immunotherapy platform that could prevent or reverse the immune reactions that cause these conditions. Patients may benefit from a more effective treatment strategy for allergies and autoimmune diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals suffering from autoimmune diseases or food allergies.
Not a fit: Patients with non-autoimmune related conditions or those not experiencing allergies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative therapies that effectively manage or cure autoimmune conditions and allergies.
How similar studies have performed: Previous research has shown promise in using similar nanoparticle approaches for immunotherapy, indicating potential for success in this novel application.
Where this research is happening
AMHERST, UNITED STATES
- STATE UNIVERSITY OF NEW YORK AT BUFFALO — AMHERST, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BALU-IYER, SATHY VENKAT — STATE UNIVERSITY OF NEW YORK AT BUFFALO
- Study coordinator: BALU-IYER, SATHY VENKAT
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acid Maltase Deficiency Disease